Corbus Pharmaceuticals Holdings, Inc.
CRBPCorbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare, inflammatory, and fibrotic diseases. The company's pipeline emphasizes its expertise in cannabinoid-based medicines, with particular interest in conditions such as cystic fibrosis, dermatomyositis, and other inflammatory disorders. Corbus aims to deliver novel treatments targeting underlying disease mechanisms to improve patient outcomes.
Company News
Corbus Pharmaceuticals has priced a public offering of 4,744,231 common stock shares and pre-funded warrants, raising approximately $75 million to fund clinical development and corporate purposes.
Corbus Pharmaceuticals plans to raise approximately $75 million through a public offering of 4,744,231 common stock shares and pre-funded warrants, with proceeds intended to fund clinical development and working capital.
Corbus Pharmaceuticals announced promising Phase 1/2 clinical trial results for CRB-701, an antibody-drug conjugate targeting Nectin-4, showing robust response rates across head and neck, cervical, and urothelial cancers with a favorable safety profile.
The cannabinoid agonist market is gaining momentum with expanding medical cannabis legalization and growing clinical validation for treating chronic pain, epilepsy, and inflammatory conditions. Over 20 pharmaceutical companies are actively developing cannabinoid agonist drugs with promising pipeline candidates.
Corbus Pharmaceuticals, a clinical-stage company focused on oncology and obesity, announced that its CEO will provide a corporate update and participate in investor meetings at the Jefferies Global Healthcare Conference.
